Claritev Corporation (CTEV)
| Market Cap | 405.89M -64.6% |
| Revenue (ttm) | 994.67M +6.3% |
| Net Income | -283.11M |
| EPS | -16.99 |
| Shares Out | 16.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,045 |
| Open | 23.36 |
| Previous Close | 23.00 |
| Day's Range | 23.36 - 24.91 |
| 52-Week Range | 11.50 - 73.68 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 46.00 (+92.07%) |
| Earnings Date | Nov 9, 2026 |
About CTEV
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical neg... [Read more]
Financial Performance
In 2025, Claritev's revenue was $965.41 million, an increase of 3.74% compared to the previous year's $930.62 million. Losses were -$284.28 million, -82.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CTEV stock is "Buy." The 12-month stock price target is $46.0, which is an increase of 92.07% from the latest price.
News
Claritev Introduces Transparency-Based Pricing, Turning Complex Public Market Data into Actionable Reimbursement Intelligence
MCLEAN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced the launch of Trans...
Claritev Appoints Jennifer Main to its Board of Directors
MCLEAN, Va., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of Directors (“...
Claritev Corporation Announces Third Quarter 2026 Earnings Conference Call
MCLEAN, Va., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more af...
Claritev selected by GDIT to support World Trade Center Health Program
Claritev (CTEV) Corporation has been selected by General Dynamics Information Technology to support the World Trade Center Health Program. The WTC Health Program is a limited federal health care progr...
Claritev Selected by GDIT to Support CDC's World Trade Center Health Program
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #GDIT--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent and fair ...
Claritev Releases 2025 Corporate Responsibility Report
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #CommunityImpact--Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a healthcare technology, data, and insights company, today announced the publi...
Claritev appoints Letham to its Board of Directors
Claritev (CTEV) announced that its Board of Directors has appointed Ben Letham as a director, effective September 14, 2026, to fill a vacancy on the Board. Letham currently serves as…
Claritev Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Healthcare costs and regulatory complexity drive demand for transparency and efficiency, fueling five consecutive quarters of growth and a return to $1 billion in revenue. Strategic investments in AI, technology modernization, and new market segments are accelerating bookings and client diversification.
Claritev Appoints Ben Letham to its Board of Directors
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #BoardOfDirectors--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of D...
Claritev Cares Helps Rural Patients Get Critical Care Closer to Home
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #ClaritevCares--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable and transpare...
Claritev Corporation Announces Participation in Upcoming Events
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that members of its management team ...
Claritev price target raised to $40 from $28 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on Claritev (CTEV) to $40 from $28 and keeps an Overweight rating on the shares.
Marpai expand relationship with Claritev
Claritev (CTEV) Corporation announced that Marpai has expanded its relationship with Claritev to bring comprehensive pre- and post-payment integrity capabilities to the health plans and claims it admi...
Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #ClaimsManagement--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX: MRAI) has ex...
Claritev price target raised to $30 from $22 at Wells Fargo
Wells Fargo raised the firm’s price target on Claritev (CTEV) to $30 from $22 and keeps an Equal Weight rating on the shares. Claritev’s Q2 beat, raised FY26 outlook, and…
Claritev Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is executing a multi-year transformation focused on digital innovation, operational excellence, and market expansion, with strong financial momentum and a robust sales pipeline. Litigation risks are being managed, and regulatory changes like the No Surprises Act are driving product growth.
Claritev price target raised to $43 from $37 at Canaccord
Canaccord raised the firm’s price target on Claritev (CTEV) to $43 from $37 and keeps a Buy rating on the shares. The firm updated its model following beat and raise…
Claritev price target raised to $45 from $40 at Citi
Citi analyst Daniel Grosslight raised the firm’s price target on Claritev (CTEV) to $45 from $40 and keeps a Buy rating on the shares.
Claritev Earnings Call Transcript: Q2 2026
Q2 results exceeded expectations with revenue up 6.6% year-over-year and record cash flow. Strong bookings and pipeline growth support raised full-year guidance, while digital transformation and AI initiatives drive efficiency and client value.
Claritev Slides: Q2 2026
Claritev has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 7, 2026.
Claritev Earnings release: Q2 2026
Claritev released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Claritev Quarterly report: Q2 2026
Claritev has published its Q2 2026 quarterly earnings report on August 7, 2026.
Claritev raises FY26 revenue view to $1B-$1.02B from $985M-$1B
Consensus $993.39M. Raises FY26 adjusted EBITDA view to $620M-$620M from $605M-$615M. Backs FY26 capital expenditures view $160M-$170M. Dalton added, “This success is most clearly reflected in our boo...
Claritev reports Q2 EPS ($3.49) vs. ($3.81) last year
Reports Q2 revenue $257.48M, consensus $244.81M. “Claritev (CTEV) once again demonstrated the strength of our vision and strategy in the second quarter of 2026, delivering financial results above expe...
Claritev Corporation Reports Second Quarter 2026 Results
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...